INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by University of New Mexico.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
University of New Mexico
Information provided by:
University of New Mexico
ClinicalTrials.gov Identifier:
NCT00322712
First received: May 5, 2006
Last updated: June 23, 2010
Last verified: March 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
| Condition |
|---|
|
Pancreatic Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer |
Resource links provided by NLM:
Further study details as provided by University of New Mexico:
| Estimated Enrollment: | 20 |
| Study Start Date: | February 2006 |
| Estimated Study Completion Date: | February 2011 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Chart Review to describe the clinical outcomes in patients pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.
Criteria
Inclusion Criteria:
Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.
Exclusion Criteria:
Not specified.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00322712
Locations
| United States, New Mexico | |
| University of New Mexico | |
| Albuquerque, New Mexico, United States, 87131 | |
Sponsors and Collaborators
University of New Mexico
Investigators
| Principal Investigator: | Fa-Chyi Lee, MD | University of New Mexico |
More Information
No publications provided
| Responsible Party: | Fa-Chyi Lee, MD; Principal Investigator, University of New Mexico - CRTC |
| ClinicalTrials.gov Identifier: | NCT00322712 History of Changes |
| Other Study ID Numbers: | INST 0603C |
| Study First Received: | May 5, 2006 |
| Last Updated: | June 23, 2010 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on June 17, 2013